Pulished Date August, 2019
ID: 878
Share on
Share on

Asia Pacific Diabetic Retinopathy Market Research Report - Segmented By Treatment Type, Indication, End User, By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Forecast, Growth | 2019 - 2024

Pulished: August, 2019
ID: 878
Pages: 142

APAC Diabetic Retinopathy Market Size & Growth (2019 - 2024)

The size of the Asia Pacific Diabetic Retinopathy Market was valued at USD 1.67 billion in 2019 and is projected to reach USD 2.44 billion by 2024, growing at a CAGR of 7.94% during the forecast period from 2019 to 2024.

Asia is predicted to show wealthy growth in the forecast period. Within the Asian region, the western pacific region accounts for a larger share of blindness due to DR when equated to South-East Asia. The major factor contributing to the increasing share of Diabetic Retinopathy among the growing economies is a huge pool of patients and increasing support and funding given by the government.

Diabetic retinopathy is considered a severe sight-threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti-VEGF drugs, laser surgery or vitrectomy depending on the severity of the condition.

Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of the global diabetic retinopathy drug market in the coming years. Rising medical procedures due to the high penetration of medical insurance and rising government initiatives for the prevention of diabetes-related risks is also believed to garner the growth of the retinopathy drug market in the future.

This research report has been segmented and sub-segmented into the following categories:

  • By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy.
  • By Indication: Non-Proliferative Diabetic Retinopathy (NPDR) (Mild, Moderate and Severe) and Proliferative Diabetic Retinopathy (PDR)).
  • By End User: Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Regionally, the Asia Pacific diabetic retinopathy market is expected to maintain the highest growth rate during the forecast period. The market growth is mainly attributed to the low-income population, lack of skilled professionals, and poor access to healthcare facilities in the region. With the emergence of combination therapy for diabetic macular edema, the Asia-Pacific region and emerging markets in LAMEA are supposed to provide market growth opportunities.

Emerging economies such as Japan and China in the APAC Diabetic Retinopathy Market are forecasting development due to the rising disposable income, a growing elderly population, increasing funding for diabetes research, diagnostic innovations, and large target populations. The Chinese diabetic retinopathy market is anticipated to achieve rapid growth during the outlook period. Japan is the largest market in the Asia-Pacific region, mainly due to high medical costs and increasing disposable income. Also, increased use of Lucentis is foreseen to drive market growth in the area.

Prominent companies in the APAC Diabetic Retinopathy Market profiled in the report are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                              

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                            

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                     

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                      

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                      

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

5. Market Segmentation                                                                              

                5.1 By Type of Treatment                                                            

                                5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug                                          

                                5.1.2 Intraocular Steroid Injection                                           

                                5.1.3 Laser Surgery                                         

                                5.1.4 Vitrectomy                                             

                5.2 By Indication                                                              

                                5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)                                      

                                                5.2.1.1 Mild                       

                                                5.2.1.2 Moderate                            

                                                5.2.1.3 Severe                  

                                5.2.2 Proliferative Diabetic Retinopathy (PDR)                                    

                5.3 By End Users                                                             

                                5.3.1 Hospitals                                  

                                5.3.2 Ophthalmic Clinics                                               

                                5.3.3 Ambulatory Surgical Centers                                           

6. Geographical Analysis                                                                              

                6.3 Asia-Pacific                                                 

                                6.1 Introduction                                              

                                6.2 China                                            

                                6.3 India                                              

                                6.4 Japan                                            

                                6.5 South Korea                               

                                6.6 Australia                                      

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

8. Market Leaders' Analysis                                                                        

                8.1 Bayer AG                                                     

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Pfizer Inc.                                                    

                8.3 Hoffmann-La Roche ltd                                                          

                8.4 Regeneron Pharmaceutical Inc.                                                         

                8.5 Novartis AG                                                

                8.6 Valeant Pharmaceutical International Inc.                                                     

                8.7 Abbott Laboratories Inc.                                                       

                8.8 Alimera Science Inc.                                                                

                8.9 Ampio Pharmaceuticals Inc.                                                

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

10. Expert Opinions                                                                        

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Diabetic Retinopathy Market By Region, From 2019-2024 (USD Billion)
  2. Asia-Pacific Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  3. Asia-Pacific Anti-Vascular Endothelial Growth Factor (VEGF) drug Market By Region, From 2019-2024 (USD Billion)
  4. Asia-Pacific Intraocular Steroid Injection Market By Region, From 2019-2024 (USD Billion)
  5. Asia-Pacific Laser Surgery Market By Region, From 2019-2024 (USD Billion)
  6. Asia-Pacific Vitrectomy Market By Region, From 2019-2024 (USD Billion)
  7. Asia-Pacific Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  8. Asia-Pacific Non-Proliferative Diabetic Retinopathy (NPDR) Market By Region, From 2019-2024 (USD Billion)
  9. Asia-Pacific Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  10. Asia-Pacific Mild Indication Market By Region, From 2019-2024 (USD Billion)
  11. Asia-Pacific Moderate Indication Market By Region, From 2019-2024 (USD Billion)
  12. Asia-Pacific Severe Indication Market By Region, From 2019-2024 (USD Billion)
  13. Asia-Pacific Proliferative Diabetic Retinopathy (PDR) Market By Region, From 2019-2024 (USD Billion)
  14. Asia-Pacific Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  15. Asia-Pacific Hospitals Market By Region, From 2019-2024 (USD Billion)
  16. Asia-Pacific Ophthalmic Clinics Market By Region, From 2019-2024 (USD Billion)
  17. Asia-Pacific Ambulatory Surgical Centers Market By Region, From 2019-2024 (USD Billion)
  18. China Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  19. China Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  20. China Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  21. China Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  22. India Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  23. India Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  24. India Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  25. India Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  26. Japan Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  27. Japan Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  28. Japan Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  29. Japan Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  30. South Korea Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  31. South Korea Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  32. South Korea Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  33. South Korea Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)
  34. Australia Diabetic Retinopathy Market By Treatment Type, From 2019-2024 (USD Billion)
  35. Australia Diabetic Retinopathy Market By Indication, From 2019-2024 (USD Billion)
  36. Australia Diabetic Retinopathy Market By Non-Proliferative Diabetic Retinopathy (NPDR) Type, From 2019-2024 (USD Billion)
  37. Australia Diabetic Retinopathy Market By End Users, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample